Targeting Tissues Throughout the Body with RNA Therapies
Arthur Suckow, co-founder and CEO of DTx Pharma, discusses the delivery challenge of RNA therapies, how DTx’s platform technology addresses these, and how a $100 million financing from earlier this year will be used to fuel its growth.